Minims Tetracainehydrochloride Bausch + Lomb Ireland Limited (Tetracaine Hydrochloride)

Tetracaine hydrochloride works by reversibly blocking voltage‑gated sodium channels on peripheral nerves in the ocular surface. This blockade stops the initiation and propagation of nerve impulses, preventing pain signals from reaching the brain and producing rapid, localized anesthesia.

The specific dose and frequency are determined by the prescribing ophthalmologist based on the procedure and patient needs. The prescriber will select the appropriate volume and number of applications to achieve adequate anesthesia while minimizing exposure.

Safety data for tetracaine hydrochloride in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Tetracaine hydrochloride offers rapid onset and a relatively longer duration of surface anesthesia compared with agents such as proparacaine. It is an ester‑type anesthetic, which may have a higher risk of corneal toxicity with repeated use, so clinicians balance efficacy against safety when selecting an agent.

Store the ophthalmic solution at ambient temperature, preferably below 25 °C. Keep it in the original sealed container, protect it from direct light and moisture, and discard any product that appears cloudy or contaminated.

The solution is applied topically to the ocular surface, typically as one or more drops directly onto the conjunctival sac. Administration is performed by a qualified eye‑care professional immediately before the intended diagnostic or surgical procedure.

Serious risks include corneal epithelial toxicity, persistent ulceration, and rare systemic allergic reactions such as anaphylaxis. Prompt recognition of severe ocular irritation or systemic symptoms is essential, and the medication should be discontinued if these occur.

Patients with a known hypersensitivity to tetracaine, other ester‑type local anesthetics, or any component of the formulation should avoid this product. Additionally, individuals with active corneal disease or severe ocular surface disorders should not receive it without specialist evaluation.